Retatrutide is the drug researchers are calling potentially the most powerful weight-loss medication ever tested — and with Phase 3 clinical trial results now landing in 2025 and 2026, the conversation is picking up fast.
A note before reading: This article discusses a medication being studied for metabolic conditions. It includes clinical information about weight, appetite, and metabolism. If you have a history of an eating disorder, disordered eating, or a complex relationship with food or your body, some of this information may feel difficult. You’re welcome to read at your own pace, skip sections, or speak with a trusted provider before engaging with this topic. Your wellbeing matters more than staying current on pharmaceutical news.
What Is Retatrutide, Anyway?
Retatrutide is an investigational medication developed by Eli Lilly — the same pharmaceutical company that makes Mounjaro and Zepbound. It is not yet approved by the FDA or any major regulatory body. As of mid-2026, it is still in Phase 3 clinical trials, with regulatory submission anticipated later in 2026 and potential approval expected sometime in 2027.
What makes retatrutide different from existing drugs in its class is its mechanism: it is a triple hormone receptor agonist, meaning it simultaneously activates three hormone receptors in the body. Most drugs currently on the market target only one or two.
Those three receptors are:
- GLP-1 (glucagon-like peptide-1) — the same receptor targeted by semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound); it regulates appetite, slows stomach emptying, and affects blood sugar
- GIP (glucose-dependent insulinotropic polypeptide) — also targeted by tirzepatide; works alongside GLP-1 to regulate insulin and metabolic function
- Glucagon — a hormone primarily involved in energy expenditure and fat metabolism; this is the unique third target that sets retatrutide apart from all currently approved medications
Because it hits all three of these receptors in a single molecule, retatrutide is sometimes called a “triple agonist” or described as a “first-in-class” drug. Eli Lilly describes it as “a single molecule that activates the body’s receptors for glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon.”
How Does It Work?
Each of the three hormones retatrutide mimics plays a different role in how the body manages hunger, blood sugar, and energy:
- GLP-1 activation suppresses appetite, slows how quickly the stomach empties, and signals fullness to the brain. It also improves insulin sensitivity and lowers blood sugar.
- GIP activation amplifies those insulin-regulating effects and may improve how the body stores and uses fat.
- Glucagon activation increases energy expenditure — meaning the body burns more calories at rest — and appears to directly target fat tissue.
The drug is administered as a once-weekly subcutaneous injection — the same delivery method as Ozempic and Zepbound. It is not a pill.
What Do the Clinical Trials Show?
Phase 2 Results
The early-phase data published in The New England Journal of Medicine in 2023 got considerable attention. In a trial of adults with obesity, participants on the highest dose (12 mg weekly) lost an average of approximately 24.2% of their body weight over 48 weeks — roughly 58 pounds for someone starting at 240 pounds. Over 90% of participants achieved at least 5% weight loss, a benchmark considered clinically meaningful for metabolic health outcomes.
Phase 3 Results (2025–2026)
The TRIUMPH clinical trial program is Eli Lilly’s Phase 3 development effort for retatrutide. Results from the first two trials have now been published:
TRIUMPH-4 (December 2025): This trial enrolled 445 adults with obesity and knee osteoarthritis. Participants taking the 12 mg dose lost an average of 28.7% of their body weight at 68 weeks — roughly 71 pounds — while those on 9 mg lost 26.4%, compared with 2.1% in the placebo group. Participants also reported substantial improvements in knee pain and physical function.
TRIUMPH-1 (May 2026): This is the largest trial to date, involving 2,339 participants. At 80 weeks, participants on the 12 mg dose lost an average of 25% of their body weight, compared with 3.9% in the placebo group. A subset of participants with severe obesity who were escalated to maximum doses over 104 weeks achieved up to 30% body weight reduction.
As Scientific American reported, a 30% average weight loss puts retatrutide “essentially on par with bariatric surgery” in terms of magnitude, which is unprecedented for a medication. Researchers quoted in the coverage called it “the largest weight loss I’ve ever seen in any medication trial.”
Additional TRIUMPH trials covering type 2 diabetes, cardiovascular outcomes, sleep apnea, chronic low back pain, and metabolic liver disease are expected to report results through 2026.
What Conditions Is It Being Studied For?
While most of the headlines focus on obesity, retatrutide is being evaluated for a range of conditions. According to Eli Lilly’s Phase 3 program, these include:
- Obesity and overweight with at least one weight-related health condition
- Type 2 diabetes
- Knee osteoarthritis
- Moderate-to-severe obstructive sleep apnea
- Chronic low back pain
- Cardiovascular and renal disease outcomes
- Metabolic dysfunction-associated steatotic liver disease (MASLD, formerly called NAFLD)
This broader scope reflects the growing understanding that these conditions are often metabolically linked — and that treating one may meaningfully affect the others.
What Are the Side Effects?
Common Side Effects
The most frequently reported side effects in clinical trials are gastrointestinal, consistent with other GLP-1-based medications:
- Nausea
- Diarrhea
- Vomiting
- Constipation
- Stomach discomfort or pain
These effects are most common during the first four to six weeks of treatment and at each dose-escalation point, and typically improve as the body adjusts. They are the primary reason some participants reduced or delayed dose increases.
Less commonly reported:
- Fatigue
- Headaches
- Mild increases in heart rate (heart rate tended to peak and then decline over time in trials)
A Notable Signal: Dysesthesia
One side effect that appeared more prominently in retatrutide trials than in those for other GLP-1 drugs is dysesthesia — an abnormal, often uncomfortable sensation in the skin, sometimes described as tingling, burning, or hypersensitivity. In the TRIUMPH-4 trial, dysesthesia was reported in 8.8% of participants on 9 mg and 20.9% of those on 12 mg, compared with 0.7% on placebo. Events were generally mild and infrequently led to people stopping the drug, but this is a signal being actively monitored.
Discontinuation Rates
Discontinuation rates due to adverse events ranged from roughly 12–18% in trials — higher than placebo groups and somewhat higher than figures seen with currently approved GLP-1 medications. Notably, some participants discontinued not because of unwanted side effects, but because they felt they were losing too much weight — an emerging and important phenomenon in this drug class.
Risks Under Monitoring
Because retatrutide targets GLP-1 receptors, it carries the same class-level precautions as existing drugs in this family:
- Pancreatitis
- Gallbladder disease
- Gastrointestinal intolerance
These effects have not been specifically linked to retatrutide in current trials, but long-term outcomes are still being established. Cardiovascular monitoring and pancreatic safety are being tracked across ongoing trials.
What We Still Don’t Know
Retatrutide is promising, but the honest picture requires acknowledging significant gaps in current knowledge:
- Long-term safety: No published data beyond approximately 68–80 weeks exists yet. What happens at 2, 5, or 10 years is unknown.
- Muscle preservation: Rapid, significant weight loss can result in loss of lean muscle mass alongside fat. Researchers and clinicians have flagged muscle preservation as a meaningful concern with GLP-1 class drugs generally, and retatrutide’s more aggressive weight loss could amplify this. Protein intake and resistance training are currently recommended strategies to mitigate this risk.
- Effects on mental health and mood: Researchers are actively studying whether GLP-1 class drugs may affect mood, depression, or other psychiatric symptoms, given that these drugs interact with brain pathways involved in appetite and reward. This is an open question specifically for retatrutide.
- What happens when you stop: With current GLP-1 medications, weight often returns when treatment is discontinued. Whether this holds for retatrutide to the same extent is not yet well-characterized.
- Cost and access: No price has been announced, but similar drugs like tirzepatide run $1,000–$1,400 per month without insurance. Cost and insurance coverage will likely determine who can realistically access retatrutide if approved.
- Regulatory timeline: As of June 2026, retatrutide has not been submitted to the FDA for approval. Approval is anticipated somewhere in 2027, depending on when Eli Lilly submits the full data package and how long FDA review takes.
Important Considerations for People with Chronic Illness or Complex Health Histories
Retatrutide has received attention not just from people with obesity-related metabolic conditions, but from a wide range of people curious about its effects. A few things worth knowing:
Eating disorders and disordered eating: Significant appetite suppression and rapid weight loss can be destabilizing — and potentially dangerous — for people who have or have had a complex relationship with food, eating, or their body. If you have a history of an eating disorder, this is a conversation to have carefully and honestly with a provider who knows your full history.
People with diabetes: A March 2026 trial showed that participants with type 2 diabetes taking retatrutide 12 mg lost an average of 16.8% of their body weight at 40 weeks. Retatrutide may become a meaningful option for this group, but, as with all medications that affect blood sugar and insulin, careful clinical management will be essential.
People with cardiovascular conditions: Dedicated cardiovascular outcomes trials are ongoing, and results are expected in 2026. Until those data are available, the cardiovascular risk-benefit picture for people with established heart disease is still incomplete.
People with mental health conditions: The interaction between GLP-1 class drugs and psychiatric symptoms is genuinely uncertain. Some research suggests potential mood benefits; other signals warrant monitoring. This is not a reason to rule the drug out, but it is a reason to discuss your full psychiatric history with your prescribing provider.
People not seeking weight loss: It’s worth noting explicitly that weight loss is not universally desired or appropriate. The research on retatrutide is conducted in populations with specific metabolic health conditions. Interest in this drug for purposes other than those studied — or in populations not represented in the trials — goes beyond what the current evidence supports.
Where Does Retatrutide Stand Right Now?
Here’s a quick snapshot of the current status as of June 2026:
- FDA status: Investigational — not approved
- Access: Clinical trials only; no prescription availability
- Approval timeline: Likely 2027 at the earliest, pending regulatory submission and FDA review
- Phase 3 results available: TRIUMPH-1 (obesity, May 2026) and TRIUMPH-4 (obesity + knee osteoarthritis, December 2025)
- Results pending: TRIUMPH-2, -3, and trials in diabetes, cardiovascular outcomes, sleep apnea, liver disease, and back pain — expected through 2026
The Bottom Line
Retatrutide is a triple-hormone receptor agonist — targeting GLP-1, GIP, and glucagon simultaneously — that has produced unprecedented weight loss results in Phase 3 clinical trials. It is being studied for obesity and a range of metabolic and musculoskeletal conditions.
It is not yet approved, not yet available by prescription, and not without risks and unknowns. Its side-effect profile is broadly similar to that of existing GLP-1 medications, with the addition of a notable dysesthesia signal and higher discontinuation rates. Long-term data, mental health effects, and muscle-preservation outcomes are areas where the evidence is still developing.
For people managing complex health situations — including chronic illness, mental health conditions, or histories of disordered eating — this is a drug that warrants careful, individualized conversation with a healthcare provider, not a conclusion drawn from headlines.